secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2026-05-28T10:07:05+00:00
Accession:  0001213900-26-061701
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA raises $3.8M via private placement; believes it regains Nasdaq compliance
-------------------------------------------------------------------------------

- Gross proceeds ~$3.8M from sale of 578,387 shares (or prefunded warrants) and 1,156,774 warrants at $6.57 per unit.
- Side letter restricts cash use until strategic alternative closes or payment obligation met; grants board observer right.
- Nasdaq notified company of non-compliance on Apr 20, 2026; after offering, company believes equity exceeds $2.5M minimum.
- Offering expected to close May 28, 2026; placement agent Lucid Capital Markets.
- Proceeds for working capital and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000121390026061701/0001213900-26-061701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000121390026061701/ea0292216-8k_endra.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-061701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer